PMID- 35222274 OWN - NLM STAT- MEDLINE DCOM- 20220331 LR - 20220401 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 13 DP - 2022 TI - J-Shaped Relationship Between Serum Prolactin and Metabolic-Associated Fatty Liver Disease in Female Patients With Type 2 Diabetes. PG - 815995 LID - 10.3389/fendo.2022.815995 [doi] LID - 815995 AB - BACKGROUND: Metabolic-associated fatty liver disease (MAFLD) has become a worldwide epidemic. Prolactin (PRL), a pituitary hormone, has been linked to MAFLD. As a result, we set out to look into the relationship between serum PRL and the risk of MAFLD in patients with type 2 diabetes mellitus (T2DM). METHODS: A total of 724 adults with T2DM were enrolled and categorized as MAFLD and non-MAFLD groups. Anthropometric data, biochemical parameters, and serum PRL levels were collected. Liver steatosis and fibrosis were assessed using FibroScan. Patients were stratified into normal PRL (NP) and high PRL (HP) groups and divided into four groups based on serum PRL quartiles. Multivariate logistic regression analysis was performed to evaluate the association between serum PRL and MAFLD risk. RESULTS: Female but not male patients with MAFLD, liver steatosis, and fibrosis had significantly lower PRL levels in the NP group but higher PRL levels in the HP group than their counterparts. The proportions of MAFLD, liver steatosis, and fibrosis were significantly decreased in the NP group but increased in the HP group across the PRL quartiles in females but not in males. After multivariate adjustment, the adjusted ORs (AORs) and 95% CI for MAFLD among females were 18.165 (3.425-96.336), 1.784 (0.658-5.002), 1.744 (0.608-4.832), and 1.00 (reference) in the NP group (Q1-Q4, P-trend < 0.001) and 1.00 (reference), 11.098 (1.819-110.356), 15.225 (1.996-116.112), and 18.211 (2.579-128.568) in the HP group (Q1-Q4, P-trend = 0.020). Such associations were also found between serum PRL and liver fibrosis in females but not in males. CONCLUSION: We observed a J-shaped association between serum PRL and the risk of MAFLD and liver fibrosis in females but not in males with T2DM, indicating that PRL may be relevant to MAFLD and its progression in a gender-specific manner. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry, number ChiCTR-OCS-12002381. CI - Copyright (c) 2022 Zhu, Ma, Huang, Li, Gao, Cai, You, Bu and Qu. FAU - Zhu, Cuiling AU - Zhu C AD - Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. AD - National Metabolic Management Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Ma, Huihui AU - Ma H AD - Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. AD - National Metabolic Management Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Huang, Dongdong AU - Huang D AD - Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Li, Guifang AU - Li G AD - Department of Cardiology, People's Hospital of Pu'er City, Pu'er, China. FAU - Gao, Jingyang AU - Gao J AD - Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. AD - National Metabolic Management Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Cai, Meili AU - Cai M AD - Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. AD - National Metabolic Management Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - You, Hui AU - You H AD - Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. AD - National Metabolic Management Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Bu, Le AU - Bu L AD - Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. AD - National Metabolic Management Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Qu, Shen AU - Qu S AD - Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. AD - National Metabolic Management Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. LA - eng SI - ChiCTR/ChiCTR-OCS-12002381 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220211 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 RN - 9002-62-4 (Prolactin) SB - IM MH - Adult MH - *Diabetes Mellitus, Type 2/complications MH - Female MH - Humans MH - Liver Cirrhosis/etiology MH - Male MH - *Non-alcoholic Fatty Liver Disease/epidemiology MH - Prolactin PMC - PMC8875202 OTO - NOTNLM OT - gender-specific difference OT - liver fibrosis OT - metabolic-associated fatty liver disease OT - prolactin OT - type 2 diabetes COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/03/01 06:00 MHDA- 2022/04/01 06:00 PMCR- 2022/01/01 CRDT- 2022/02/28 05:34 PHST- 2021/11/16 00:00 [received] PHST- 2022/01/10 00:00 [accepted] PHST- 2022/02/28 05:34 [entrez] PHST- 2022/03/01 06:00 [pubmed] PHST- 2022/04/01 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fendo.2022.815995 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2022 Feb 11;13:815995. doi: 10.3389/fendo.2022.815995. eCollection 2022.